Bayesian decision procedures with application to dose-finding studies

International Journal of Pharmaceutical Medicine

Volumn 11, Issue 4, 1997, Pages 201-208

  Whitehead, John ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Bayesian methods; Clinical trial; Decision procedures; Dose finding; Phase I; Phase II

Indexed keywords

QUERCETIN;

BAYES THEOREM; CANCER; CLINICAL TRIAL; DECISION THEORY; DRUG DEVELOPMENT; DRUG DOSE; HUMAN; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0030848713     PISSN: 13649027     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bradford Hill A. Memories of the British streptomycin trial in tuberculosis: The first randomised clinical trial. Controlled Clinical Trials 1990; 11:77-79.
2. Castle W, Fuller R, Hall J, Palmer, J. Serevant nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular branchodilator treatment. British Medical Journal im-, 306:1034-1037.
3. Colton J. A model for selecting one of two medical treatments. Journal of the American Statistical Association 1963; 58:388-400.
4. Anscombe FJ. Sequential medical trials. Journal of the American Statistical Association 1963; 58:365-383.
5. Cornfield J. A Bayesian test of some classical hypotheses - with application to sequential clinical trials. Journal of the American Statistical Association^^; 61:577-594.
6. Zelen M. Play-the-winner rule and the controlled clinical trial. Journal of the American Statistical Association 1969; 64:134-146.
7. Bather JA. On the allocation of treatments in sequential medical trials. International Statistical Review 1985; 53:1-13.
8. Palmer CR. A comparative phase II clinical trials procedure for choosing the best of three treatments. Statistics in Medicine 1991; 10:1327-1340.
9. Sylvester RJ, Staquet ML Design of phase II clinical trials in cancer using decision theory. Cancer Treatment Reports 1980; 64:519-524.
10. Sylvester RJ. A Bayesian approach to the design of phase II clinical trials. Biometrics 1988; 44: 823-836.
11. Hilden J. Corrected loss calculation for phase II trials. Reader reaction Biometrics 1990; 46:535-538.
12. Brünier HC and Whitehead J. Sample sizes for phase II clinical trials derived from Bayesian decision theory, tatistics in Medicine 1994; 13:2493-2502.
13. Whitehead J. Designing phase II studies in the context of a programme of clinical research. Biometrics 1985; 41:373-383.
14. Whitehead J. Sample sizes for phase I and phase III clinical trials, an integrated approach. Statistics in Medicine 1986; 5:459-464.
15. Simon R, Thall, PF, Ellenberg, SS. New designs for the selection of treatments to be tested in randomised clinical trials. Statistics in Medicine 1994; 13:417-430.
16. Chen, TT and Simon R. A multiple decision procedure in clinical trials. Statistics in Medicine 1994; 13:431-446.
17. Dixon, WJ, Mood AM. A method for obtaining an analysing sensitivity data. Journal of the American Statistical Association 1948; 43:109-126.
18. 18.0'Quigley J, Pepe M, Fisher L Continual Reassessment Method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46:33-48.
19. 19.0'Quigley J, Chevret S. Methods for dose finding studies in cancer clinical trials: a review and results of a Monte-Carlo study. Statistics in Medicine 1991; 10:1647-1664.
20. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM. A comparison of two phase I designs. Statistics in Medicine 1994; 13:1799-1806.
21. Faries D. Practical modifications of the continual reassessment method for phase I cancer clinical trials. Journal of Biopharmaceutical Statistics 1994; 4:147-164.
22. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 1995; 14:1149-1161.
23. Whitehead J, Brünier H. Bayesian decision procedures for dose determining experiments. Statistics in Medicine 1995; 14:885-893.
24. Whitehead J, and Williamson D. An evaluation of Bayesian decision procedures for dose-finding studies. Technical Report 96/8,1996, Department of Applied Statistics, University of Reading.
25. Tsutakawa RK. Bayesian inference for bioassay. Technical Report 1975; 5. Mathematical Sciences, University of Missouri, Columbia.
26. Collett D. Modelling Binary Data. London: Chapman and Hall, 1991.
27. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J, Kerr DJ. Phase I clinical trial of the flavonoid quercetin - pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clinical Cancer Research 1966; 2:659-668.